M Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
Lightcast lands £20m in funding led by ARCH Venture Partners to advance single-cell analysis platform
Lightcast is a life science tools startup that develops a benchtop platform for functional single-cell analysis. Its technology enables researchers to directly measure how individual cells behave, supporting applications such as antibody discovery, cell therapy, and immunology research.
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
- 3(12 months)
- m-ventures.com
- Update Information
More venture news
- 21 Jul 2026
Mach42Mach42 raises a £7m pre-Series A round led by IP Group to speed up analog circuit verification for semiconductor engineers
ExtensionDeep Tech - 9 Jul 2026
Alchemab TherapeuticsAlchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases
ExtensionLife Sciences - 23 Jun 2026
TRIMTECH TherapeuticsTRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
ExtensionLife Sciences
